Baxter buyback seeks $2 billion

DEERFIELD -- Baxter International Inc., maker of hemophilia drugs and the recalled blood thinner heparin, may buy back as much as $2 billion in additional shares after completing an existing repurchase program. The company has less than $700 million remaining from a $2 billion repurchase authorized a year ago, Baxter said Tuesday in a statement.